These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26011102)

  • 1. Increased tumor cell expression of Axl is a marker of aggressive features in breast cancer among African women.
    Ahmed L; Nalwoga H; Arnes JB; Wabinga H; Micklem DR; Akslen LA
    APMIS; 2015 Aug; 123(8):688-96. PubMed ID: 26011102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer.
    Nalwoga H; Ahmed L; Arnes JB; Wabinga H; Akslen LA
    PLoS One; 2016; 11(1):e0146823. PubMed ID: 26760782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
    Abdel-Rahman WM; Al-Khayyal NA; Nair VA; Aravind SR; Saber-Ayad M
    World J Gastroenterol; 2017 May; 23(19):3440-3448. PubMed ID: 28596680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axl receptor tyrosine kinase expression in breast cancer.
    D'Alfonso TM; Hannah J; Chen Z; Liu Y; Zhou P; Shin SJ
    J Clin Pathol; 2014 Aug; 67(8):690-6. PubMed ID: 24904064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast.
    Berclaz G; Altermatt HJ; Rohrbach V; Kieffer I; Dreher E; Andres AC
    Ann Oncol; 2001 Jun; 12(6):819-24. PubMed ID: 11484958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axl Is a Potential Cancer Prognostic Marker for the Migration and Invasion of Nasopharyngeal Carcinoma.
    Jiang C; Zhou L; Wang H; Zhang Q; Xu Y
    Adv Clin Exp Med; 2016; 25(3):531-7. PubMed ID: 27629742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational and Immunohistochemical Analyses Highlight AXL as a Potential Prognostic Marker for Ovarian Cancer Patients.
    Lozneanu L; Pinciroli P; Ciobanu DA; Carcangiu ML; Canevari S; Tomassetti A; Căruntu ID
    Anticancer Res; 2016 Aug; 36(8):4155-63. PubMed ID: 27466525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
    Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
    Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Expression of Vimentin and Axl in Breast Cancer.
    Tanaka K; Tokunaga E; Inoue Y; Yamashita N; Saeki H; Okano S; Kitao H; Oki E; Oda Y; Maehara Y
    Clin Breast Cancer; 2016 Dec; 16(6):520-526.e2. PubMed ID: 27506606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axl is a prognostic marker in oral squamous cell carcinoma.
    Lee CH; Yen CY; Liu SY; Chen CK; Chiang CF; Shiah SG; Chen PH; Shieh YS
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S500-8. PubMed ID: 21842265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
    Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S
    Breast Cancer Res Treat; 2016 Jan; 155(2):235-51. PubMed ID: 26759246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
    Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
    Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
    Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
    Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study.
    Bardol T; Eslami-S Z; Masmoudi D; Alexandre M; Duboys de Labarre M; Bobrie A; D'Hondt V; Guiu S; Kurma K; Cayrefourcq L; Jacot W; Alix-Panabières C
    Cancer Med; 2024 Jan; 13(1):e6843. PubMed ID: 38132919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
    Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS
    Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
    Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I
    Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA 34a-AXL Axis Regulates Vasculogenic Mimicry Formation in Breast Cancer Cells.
    Lim D; Cho JG; Yun E; Lee A; Ryu HY; Lee YJ; Yoon S; Chang W; Lee MS; Kwon BS; Kim J
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.
    Falcone I; Conciatori F; Bazzichetto C; Bria E; Carbognin L; Malaguti P; Ferretti G; Cognetti F; Milella M; Ciuffreda L
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Axl and Mer kinases in cancer.
    Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S
    Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.